Yu-Lin Sun1, Fei Liu1, Fang Liu1, Xiao-Hang Zhao1. 1. Yu-Lin Sun, Fei Liu, Fang Liu, Xiao-Hang Zhao, State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Abstract
AIM: To investigate the expression characteristics of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) mRNA and protein in cell lines and tissues of esophageal squamous cell carcinoma (ESCC). METHODS: Western blotting was used to assess the expression of HNRNPH1 protein in seven ESCC cell lines and 30 paired fresh tissue specimens. The subcellular localization of HNRNPH1 was determined by immunofluorescence in ESCC cells. The RNA sequencing data from 87 patients with ESCC were obtained from the cancer genome atlas (TCGA), and the expression and clinical characteristics analysis of different transcript variants of HNRNPH1 were evaluated in this dataset. In addition, immunohistochemistry was carried out to detect the expression of HNRNPH1 protein in 125 patients. RESULTS: The expression of HNRNPH1 protein varied across different ESCC cell lines. It was exclusively restricted to the nucleus of the ESCC cells. There are two transcript variants of the HNRNPH1 gene. Variant 1 was constitutively expressed, and its expression did not change during tumorigenesis. In contrast, levels of variant 2 were low in non-tumorous tissues and were dramatically increased in ESCC (P = 0.0026). The high levels of variant 2 were associated with poorer differentiated tumors (P = 0.0287). Furthermore, in paired fresh tissue specimens, HNRNPH1 protein was overexpressed in 73.3% (22/30) of neoplastic tissues. HNRNPH1 was significantly upregulated in ESCC, with strong staining in 43.2% (54/125) of tumor tissues and 22.4% (28/125) of matched non-cancerous tissues (P = 0.0005). Positive HNRNPH1 expression was significantly associated with poor tumor differentiation degree (P = 0.0337). CONCLUSION: The different alternative transcript variants of HNRNPH1 exhibited different expression changes during tumorigenesis. Its mRNA and protein were overexpressed in ESCC and associated with poorer differentiation of tumor cells. These findings highlight the potential of HNRNPH1 in the therapy and diagnosis of ESCC.
AIM: To investigate the expression characteristics of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) mRNA and protein in cell lines and tissues of esophageal squamous cell carcinoma (ESCC). METHODS: Western blotting was used to assess the expression of HNRNPH1 protein in seven ESCC cell lines and 30 paired fresh tissue specimens. The subcellular localization of HNRNPH1 was determined by immunofluorescence in ESCC cells. The RNA sequencing data from 87 patients with ESCC were obtained from the cancer genome atlas (TCGA), and the expression and clinical characteristics analysis of different transcript variants of HNRNPH1 were evaluated in this dataset. In addition, immunohistochemistry was carried out to detect the expression of HNRNPH1 protein in 125 patients. RESULTS: The expression of HNRNPH1 protein varied across different ESCC cell lines. It was exclusively restricted to the nucleus of the ESCC cells. There are two transcript variants of the HNRNPH1 gene. Variant 1 was constitutively expressed, and its expression did not change during tumorigenesis. In contrast, levels of variant 2 were low in non-tumorous tissues and were dramatically increased in ESCC (P = 0.0026). The high levels of variant 2 were associated with poorer differentiated tumors (P = 0.0287). Furthermore, in paired fresh tissue specimens, HNRNPH1 protein was overexpressed in 73.3% (22/30) of neoplastic tissues. HNRNPH1 was significantly upregulated in ESCC, with strong staining in 43.2% (54/125) of tumor tissues and 22.4% (28/125) of matched non-cancerous tissues (P = 0.0005). Positive HNRNPH1 expression was significantly associated with poor tumor differentiation degree (P = 0.0337). CONCLUSION: The different alternative transcript variants of HNRNPH1 exhibited different expression changes during tumorigenesis. Its mRNA and protein were overexpressed in ESCC and associated with poorer differentiation of tumor cells. These findings highlight the potential of HNRNPH1 in the therapy and diagnosis of ESCC.
Authors: E Sueoka; N Sueoka; Y Goto; S Matsuyama; H Nishimura; M Sato; S Fujimura; H Chiba; H Fujiki Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: Dong-Ho Kim; Marc-Andre Langlois; Kwang-Back Lee; Arthur D Riggs; Jack Puymirat; John J Rossi Journal: Nucleic Acids Res Date: 2005-07-15 Impact factor: 16.971
Authors: Youn-Bok Lee; Han-Jou Chen; João N Peres; Jorge Gomez-Deza; Jan Attig; Maja Stalekar; Claire Troakes; Agnes L Nishimura; Emma L Scotter; Caroline Vance; Yoshitsugu Adachi; Valentina Sardone; Jack W Miller; Bradley N Smith; Jean-Marc Gallo; Jernej Ule; Frank Hirth; Boris Rogelj; Corinne Houart; Christopher E Shaw Journal: Cell Rep Date: 2013-11-27 Impact factor: 9.423
Authors: Prasath Pararajalingam; Krysta M Coyle; Sarah E Arthur; Nicole Thomas; Miguel Alcaide; Barbara Meissner; Merrill Boyle; Quratulain Qureshi; Bruno M Grande; Christopher Rushton; Graham W Slack; Andrew J Mungall; Constantine S Tam; Rishu Agarwal; Sarah-Jane Dawson; Georg Lenz; Sriram Balasubramanian; Randy D Gascoyne; Christian Steidl; Joseph Connors; Diego Villa; Timothy E Audas; Marco A Marra; Nathalie A Johnson; David W Scott; Ryan D Morin Journal: Blood Date: 2020-07-30 Impact factor: 22.113